Literature DB >> 33546741

Fixed drug eruption and anaphylaxis induced concurrently by erdosteine: a case report.

Da Woon Sim1, Ji Eun Yu2, Young-Il Koh2.   

Abstract

BACKGROUND: Erdosteine is used as a mucolytic agent and has a low incidence of adverse drug reactions, most of which are gastrointestinal and mild. Moreover, drug antigens rarely induce multiple simultaneous immunologic reactions. Only one previous case report has demonstrated hypersensitivity reaction induced by erdosteine. Here, we report a case of fixed drug eruption and anaphylaxis, which were concurrently induced by erdosteine. The association between the symptoms and erdosteine was proven by a drug provocation test. CASE
PRESENTATION: A 35-year-old woman presented with recurrent angioedema and pruritic rash on the hands, which developed within 2 h following the administration of drugs, including erdosteine, for acute upper respiratory infection. Her rash was characterized by well-defined erythematous plaques, which recurred at the same site following the administration of the medications. She also experienced angioedema of the lips. Fixed drug eruption was considered after excluding other possible causes for the presented skin lesions. A drug provocation test confirmed that fixed drug eruption on both hands had occurred after administration of erdosteine, suggesting that erdosteine was the cause of the allergic reaction. However, she also experienced angioedema, isolated wheal, and laryngeal edema; thus, IgE-mediated type I hypersensitivity could also be concurrently occurring with the fixed drug eruption.
CONCLUSIONS: We report about a patient who was diagnosed with two different hypersensitivity reactions concurrently induced by erdosteine. We also demonstrate that patients may exhibit multiple simultaneous symptoms that usually arise from overlapping of different hypersensitivity mechanisms. Physicians should be aware of the possibility that some patients who are allergic to certain drugs could exhibit several symptoms caused by different mechanisms of hypersensitivity reactions simultaneously.

Entities:  

Keywords:  Anaphylaxis; Erdosteine; Fixed drug eruption; Hypersensitivity reaction; Simultaneous drug reaction

Year:  2021        PMID: 33546741      PMCID: PMC7866636          DOI: 10.1186/s13223-021-00517-6

Source DB:  PubMed          Journal:  Allergy Asthma Clin Immunol        ISSN: 1710-1484            Impact factor:   3.406


  20 in total

1.  Life-threatening, multiple hypersensitivity reactions induced by rifampicin in one patient with pulmonary tuberculosis.

Authors:  Roberto Luzzati; Donatella Giacomazzi; Fabio Franchi; Monica Barcobello; Sandro Vento
Journal:  South Med J       Date:  2007-08       Impact factor: 0.954

2.  Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease.

Authors:  Maurizio Moretti
Journal:  Expert Rev Respir Med       Date:  2007-12       Impact factor: 3.772

3.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

Review 4.  Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis.

Authors:  Mario Cazzola; Luigino Calzetta; Clive Page; Paola Rogliani; Maria Gabriella Matera
Journal:  Pulm Pharmacol Ther       Date:  2017-12-09       Impact factor: 3.410

Review 5.  Anaphylaxis and urticaria.

Authors:  Kelli W Williams; Hemant P Sharma
Journal:  Immunol Allergy Clin North Am       Date:  2014-11-21       Impact factor: 3.479

Review 6.  Fixed drug eruptions. Incidence, recognition, and avoidance.

Authors:  A Y Lee
Journal:  Am J Clin Dermatol       Date:  2000 Sep-Oct       Impact factor: 7.403

Review 7.  Dapsone-associated fixed drug eruption.

Authors:  Daniel Garcia; Philip R Cohen
Journal:  Expert Rev Clin Pharmacol       Date:  2017-04-28       Impact factor: 5.045

Review 8.  Erdosteine: antitussive and anti-inflammatory effects.

Authors:  Roberto W Dal Negro
Journal:  Lung       Date:  2008-01-10       Impact factor: 2.584

9.  Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.

Authors:  Paola Rogliani; Maria Gabriella Matera; Clive Page; Ermanno Puxeddu; Mario Cazzola; Luigino Calzetta
Journal:  Respir Res       Date:  2019-05-27

Review 10.  Mucoactive Agents in the Therapy of Upper Respiratory Airways Infections: Fair to Describe Them Just as Mucoactive?

Authors:  Francesco Scaglione; Orlando Petrini
Journal:  Clin Med Insights Ear Nose Throat       Date:  2019-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.